Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 5 of 5 results for serplulimab

  1. Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]

    In development Reference number: GID-TA11405 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Serplulimab with chemotherapy for neoadjuvant and adjuvant treatment of untreated gastric cancer [ID6760]

    Awaiting development Reference number: GID-TA11975 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Serplulimab with carboplatin and nab-paclitaxel for untreated advanced squamous non-small cell lung cancer [TSID12413]

    Awaiting development Reference number: GID-TA12040 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Serplulimab with chemotherapy for untreated PD-L1-positive unresectable advanced or recurrent oesophageal squamous cell cancer [TSID12411]

    Awaiting development Reference number: GID-TA12038 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Serplulimab with pemetrexed and carboplatin for untreated EGFR and ALK mutation-negative advanced non-squamous non-small-cell lung cancer [TSID12412]

    Awaiting development Reference number: GID-TA12039 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development